No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 458 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Targeted prostate cancer screening: Are we there yet? October 20, 2021 NHS England change of chief executive – what does it mean... August 19, 2021 Study Finds That Gut Bacteria Could Be Used to Minimize Digestive... May 28, 2021 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... January 27, 2020 Load more HOT NEWS Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... 3D-Printed Surgical Guides Are Helping Surgeons Save More Breast Tissue While... Nurse Who Battled Cancer While In School Surprises Her Dad With... Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients...
